Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr. Reddy’s Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nations, plus Iceland, Liechtenstein, and Norway. Developed and manufactured by Alvotech, AVT03 will be marketed by Dr. Reddy’s in Europe and the US, offering a new option for bone health management.🕒 1 min read
Dr. Reddy’s Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nations, plus Iceland, Liechtenstein, and Norway. Developed and manufactured by Alvotech, AVT03 will be marketed by Dr. Reddy’s in Europe and the US, offering a new option for bone health management.
Continue Reading
- US To Suspend Visa Processing Of 75 Nations Including Russia, Iran: Report
-
Why Attacks Near Iran’s Bushehr Nuclear Plant Alarm The Gulf
-
Krunal Pandya Breaks Silence On Relationship With Brother Hardik Pandya Amid Rift Rumours: “Good Conversation”
- India U19 Team Interacts With Sachin Tendulkar Ahead Of Crucial Pakistan Clash In World Cup
-
“Why Not Take Oil?” 4 Decades Before War, Trump Was Already Eyeing Iran
- Warren Buffett To Stop Donations To Gates Foundation Over Epstein Files
-
PCB Lies Exposed As Franchise Owner Contradicts Mohsin Naqvi In Big ‘PSL” Verdict
-
Opinion: Opinion | Amid Trump’s War On The World, How Effective Really Is India’s Strategic Autonomy?
-
“Won’t End Well For India”: Trump Aide Doubles Down On ‘Tariff Maharaja’ Jab
-
Russia Releases Video Of Drone It Claims Was Used To Attack Putin’s Home
